UK-based Cycle Pharmaceuticals has signed an agreement with Catalent to develop formulations targeting rare disease patients. This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalent's Zydis oral disintegrating tablet (ODT) and Zydis Ultra technologies.
Zydis technology is recognised as one of the world's best performing ODTs, and has well-established advantages over conventional oral dosage forms, including improved patient compliance, adherence and convenience. The Zydis Ultra platform is the company's next-generation ODT technology and allows for increased drug load and better taste masking to be incorporated into its proven Zydis ODT dosage form.
Commenting on the agreement, Antonio Benedetti, CEO of Cycle said: "Cycle's core area of expertise is to improve rare disease medicines in order to make life easier for patients of all ages. These drug products will benefit patients with a broad range of unmet needs."
Benedetti added: "Zydis technology has consistently proven its effectiveness in overcoming challenges faced by patients, such as swallowing difficulties and large pill burdens. Working in partnership with Catalent to apply the Zydis technology to Cycle's product pipeline will be life-changing for both patients and their caregivers."
Jonathan Arnold, President of Catalent's Oral Drug Delivery business added: "Catalent has proven experience and expertise in drug formulation and working with partners to bring new therapies to market quickly. The Zydis technology platform has been shown to be very versatile and effective in developing easy-to-administer dose forms for innovators, and having evaluated Cycle's molecules at our Swindon, UK, facility, we believe them to be excellent candidates for further development."
Zydis and Zydis Ultra are registered trademarks of RP Scherer Technologies, a wholly-owned subsidiary of Catalent.
